Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
QGEN Qiagen NV
49.250
+0.360+0.74%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-6.57% 499.63M -9.13% 515.51M 10.79% 628.39M 20.39% 2.25B
Operating revenue
-6.57% 499.63M -9.13% 515.51M 10.79% 628.39M 20.39% 2.25B
Cost of revenue
-9.59% 178.58M -6.88% 184.49M 8.55% 213.42M 25.60% 800.84M
Gross profit
-4.79% 321.05M -10.34% 331.02M 11.98% 414.97M 17.69% 1.45B
Operating expense
0.62% 197.18M 2.63% 204.11M 0.87% 202.15M 14.06% 792.97M
Selling and administrative expenses
1.57% 145.46M 7.08% 151.42M 3.59% 152.85M 11.25% 584.47M
-Selling and marketing expense
1.53% 114.58M 7.70% 118.89M 4.17% 118.5M 10.32% 456.39M
-General and administrative expense
1.70% 30.88M 4.87% 32.53M 1.62% 34.35M 14.68% 128.08M
Research and development costs
1.24% 48.87M -4.32% 49.9M -2.23% 46.38M 27.43% 189.96M
Depreciation amortization depletion
-36.32% 2.85M -47.39% 2.8M -46.06% 2.92M -10.90% 18.54M
-Depreciation and amortization
-36.32% 2.85M -47.39% 2.8M -46.06% 2.92M -10.90% 18.54M
Operating profit
-12.31% 123.88M -25.48% 126.91M 25.05% 212.82M 22.40% 657.85M
Net non-operating interest income expense
43.85% -6.35M 21.10% -9.32M 5.08% -11.31M 26.70% -44.92M
Non-operating interest income
204.47% 9.94M 107.26% 4.34M 37.33% 2.22M -4.75% 9.56M
Non-operating interest expense
11.74% 16.29M -1.78% 13.66M -0.01% 13.54M -23.61% 54.48M
Other net income (expense)
-201.39% -21.81M 76.03% -2.06M -818.73% -5.99M 135.16% 12.91M
Gain on sale of security
-- -- -- -- -103.25% -235K -- --
Special income (charges)
-179.28% -26.22M 47.45% -4.75M 9.97% -5.75M 81.62% -27.76M
-Less:Restructuring and merger&acquisition
179.28% 26.22M -47.45% 4.75M -9.97% 5.75M -81.49% 27.76M
-Less:Impairment of capital assets
-- -- -- -- -- -- -- 0
Other non- operating income (expenses)
-- 4.41M -- 2.69M -- -- -64.43% 40.67M
Income before tax
-36.80% 95.72M -22.93% 115.52M 22.89% 195.52M 42.41% 625.83M
Income tax
-27.25% 13.32M -34.61% 18.86M 34.59% 40.21M 41.04% 113.23M
Net income
-38.11% 82.39M -20.15% 96.66M 20.19% 155.31M 42.71% 512.6M
Net income continuous Operations
-38.11% 82.39M -20.15% 96.66M 20.19% 155.31M 42.71% 512.6M
Minority interest income
Net income attributable to the parent company
-38.11% 82.39M -20.15% 96.66M 20.19% 155.31M 42.71% 512.6M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-38.11% 82.39M -20.15% 96.66M 20.19% 155.31M 42.71% 512.6M
Basic earnings per share
-37.93% 0.36 -20.75% 0.42 19.30% 0.68 43.31% 2.25
Diluted earnings per share
-36.84% 0.36 -19.23% 0.42 19.64% 0.67 44.44% 2.21
Dividend per share
Currency Unit
USDUSDUSDUSD
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
CEO: Mr. Thierry Bernard
Market: NYSE
Listing Date: 07/03/2006
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist